

FFW  
PATENT

Attorney Docket No. UM-08192

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Gary D. Glick *et al.*

Serial No.: 10/634,114

Group No.:

Filed: 08/04/03

Examiner:

Entitled: **Compositions and Methods Relating to Novel  
Compounds and Targets Thereof****INFORMATION DISCLOSURE  
STATEMENT TRANSMITTAL**Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450**CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8(a)(1)(i)(A)**

I hereby certify that this correspondence (along with any referred to as being attached or enclosed) is, on the date shown below, being deposited with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.


Dated: June 16, 2004By: 

Mary Ellen Waite

Sir or Madam:

Enclosed please find an Information Disclosure Statement and Form PTO-1449, including copies of the references contained thereon, for filing in the U.S. Patent and Trademark Office.

This Information Disclosure Statement is being filed before the issuance of a first Office Action, therefore Applicant believes no fee is required. If the Commissioner deems otherwise the Commissioner is hereby authorized to charge any additional fee or credit overpayment to our Deposit Account No. 08-1290. **An originally executed duplicate of this transmittal is enclosed for this purpose.**

Dated: June 16, 2004Robert A. Goetz  
Registration No. 55,210MEDLEN & CARROLL, LLP  
101 Howard Street, Suite 350  
San Francisco, California 94105  
608/218-6900



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Gary D. Glick *et al.*

Serial No.: 10/634,114

Group No.:

Filed: 08/04/03

Examiner:

Entitled: **Compositions and Methods Relating to Novel  
Compounds and Targets Thereof**

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**CERTIFICATE OF MAILING UNDER 37 CFR § 1.8(a)**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on June 16, 2004.

By: 

Mary Ellen Waite

Sir or Madam:

The citations listed below, copies attached, may be material to the examination of the above-identified application, and are therefore submitted in compliance with the duty of disclosure defined in 37 C.F.R. §§ 1.56 and 1.97. The Examiner is requested to make these citations of official record in this application.

- U.S. Patent No. 4,946,778
- U.S. Patent No. 4,076,823
- U.S. Patent No. 4,110,337
- U.S. Patent No. 4,495,101
- U.S. Patent No. 4,751,223
- U.S. Patent No. 5,776,946
- U.S. Patent No. 5,324,726
- U.S. Patent No. 5,597,915
- U.S. Patent No. 5,041,438

- U.S. Patent No. 5,861,380
- U.S. Patent No. 5,861,380
- U.S. Patent No. 6,004,942
- U.S. Patent No. 6,080,588
- U.S. Patent No. 3,415,814
- U.S. Patent No. 3,384,635
- U.S. Patent No. 3,261,828
- U.S. Patent No. 5,288,514
- U.S. Patent Application 20010016583
- WO 00/19200
- EPO 0 349 949 A2
- WO 90/05305
- Köhler and Milstein, *Nature*, 256:495-497 [1975]
- Kozbor *et al.*, *Immunol. Today*, 4:72 [1983]
- Cole *et al.*, in *Monoclonal Antibodies and Cancer Therapy*, Alan R. Liss, Inc., pp. 77-96 [1985]
- Huse *et al.*, *Science*, 246:1275-1281 [1989]
- Adachi, M., et al., "Aberrant Transcription Caused by the Insertion of an Early Transposable Element in an Intron of the Fas Antigen Gene of *Ipr* Mice," *PNAS. USA*- 90:1756-1760 (1993)
- Adelman, N.E., et al., "Treatment of (NZB X NZW)F1 Disease with Anti-I-A Monoclonal Antibodies; *J. Exp. Med.*- 158:1350-1355 (1983)
- Baader, S.L., et al., "Uptake and Cytotoxicity of Ascorbic Acid and Dehydroascorbic Acid in Neuroblastoma (SK-N•SH) and Neuroedodermal (SK-N-LO) Cells," *Anticancer Research*-14:221-228 (1994)
- Beale, P.J., et al., "BCL-2 Family Protein Expression and Platinum Drug Resistance in Ovarian Carcinoma," *British Journal of Cancer*- 82 (2) :436-440 (2000)
- Boojamra, C.G., et al., "Solid-Phase Synthesis of 1,4-Benzodiazepine-2,5-Diones. Library Preparation and Demonstration of Synthesis Generality," *J. Org Chem.*-62:1240-1256 (1997)

- Bunin, B.A., et al., "A General and Expedient Method for the Solid-Phase Synthesis of 1,4-Benzodiazepine Derivatives," J. Am. Chem. Soc. -114:10997-10998 (1992)
- Bunin, B.A., et al., "The Combinatorial Synthesis and Chemical and Biological Evaluation of a 1,4-Benzodiazepine Library," PNAS USA-91:4708-4712 (1994)
- Chumakov, A.M., et al., "Analysis of p53 Transactivation Through High-Affinity Binding Sites," Oncogene-8:3005-3011 (1993)
- Cohen, P.L., et al., "Lpr and gld: Single Gene Models of Systemic Autoimmunity and Lymphoproliferative Disease," Annu. Rev. Immunol. - 9:243-269 (1991)
- Crabtree, R.H., "A New Type of Hydrogen Bond," Science 282:2000-2001 1998
- Desoize, B., "Anticancer Drug Resistance and Inhibition of Apoptosis," Anticancer Research -14:2291-2294 1994
- Doble, A., et al., "Labelling of Peripheral-Type Benzodiazepine Binding Sites in Human Brain with [<sup>3</sup>H]11195: Anatomical and Subcellular Distribution," Brain Research Bulletin,18:49-61 1987
- Donadio, J.V., et al., "Immunosuppressive Drug Therapy in Lupus Nephritis," American Journal of Kidney Diseases - 21(3):239-250 1993
- Ermak, T.H., et al., "Treatment of Murine Lupus with Monoclonal Antibody to L3T4," Laboratory Investigation - 61(4):447-456 1989
- Gallant, J.E., et al., "Incidence and Natural History of Cytomegalovirus Disease in Patients with Advanced Human Immunodeficiency Virus Disease Treated with Zidovudine," The Journal of Infectious Diseases -166:1223-1227 1992
- Garcia-Calvo, M., et al. "Inhibition of Human Caspases by Peptide-Based and Macromolecular Inhibitors," The Journal of Biological Chemistry - 273(49):32608-32613 1998
- Gorczyca, W., et al., "Induction of DNA Strand Breaks Associated with Apoptosis During Treatment of Leukemias," Leukemia - 7(5):659-670 1993

- Gordon, C., et al., "Chronic Therapy with Recombinant Tumor Necrosis Factor- $\alpha$  in Autoimmune NZB/NZW Fi Mice," *Clinical Immunology and Immunopathology*- 52:421-434 1989
- Gordon, E.M., et al., "Applications of Combinatorial Technologies to Drug Discovery. 2. Combinatorial Organic Synthesis, Library Screening Strategies, and Future Directions," *Journal of Medicinal Chemistry*- 37(10):1385-1401 1994
- Hahn, B.H., et al., "Influence of Cyclophosphamide and Other Immunosuppressive Drugs on Immune Disorders and Neoplasia in NZB/NZW Mice," *Arthritis and Rheumatism* -18(2):145-152 1975
- Hang, L., et al., "A Spontaneous Rheumatoid Arthritis-Like Disease in MR/1 Mice," *J. Ex p. Mod.* -155:1690-1701 1982
- Horowitz, R.E., et al., "Cyclophosphamide Treatment of Mouse Systemic Lupus Erythematosus," *Laboratory Investigation* - 21(3):199-206 1969
- Itoh, N., et al., "The Polypeptide Encoded by the cDNA for Human Cell Surface Antigen Fas Can Mediate Apoptosis," *Cell* - 66:233-243 1991
- Koopman, W.J., et al., "The MRL-Ipr/lpr Mouse. A Model for the Study of Rheumatoid Arthritis," *Scand. J. Rheumatolo* - Suppl 75:284-o289 1988
- Korsmeyer, S.J., "Bcl-2 Initiates a New Category of Oncogenes: Regulators of Cell Death," *Blood* - 80(4):879-886 1992
- Liu, J.R., et al., "Bcl<sub>XL</sub> is Expressed in Ovarian Carcinoma and Modulates Chemotherapy-induced Apoptosis," *Gynecologic Oncology* - 70:398-403 1998
- Los, M., et al., "The Role of Caspases in Development, Immunity, and Apoptotic Signal Transduction: Lessons from Knockout Mice," *Immunity* -10:629-639 1999
- Luria, et al., "General Virology - 3rd edition, . 436-446 1978 - Eds. John Wiley & Sons, New York
- Marino, M., et al., "Prevention of Systemic Lupus Erythematosus in MRL/Ipr Mice by Administration of an Immunoglobulin-Binding peptide," *Nature Biotechnology* -18:735-739 2000

- McDonnell, T.J., et al., "Progression from Lymphoid Hyperplasia to High-Grade Malignant Lymphoma in Mice Transgenic for the t(14;18)," *Nature* - 349:254-256 1991
- Nagata, S., "Human Autoimmune Lymphoproliferative Syndrome, a Defect in the Apoptosis-Inducing Fas Receptor: A Lesson from the Mouse Model," *J. Hum. Genet* - 43:2-8 1998
- Okuyama, H., et al., "Analysis of Defective Delayed-Type Hypersensitivity in Autoimmune Mice Bearing *lpr* Gene," *Clin. Exp. Immunol* - 63:87-94 1986
- Okuyama, H., et al., "Effect of Cyclophosphamide Pretreatment on Defective Delayed-Type Hypersensitivity in Autoimmune-Prone MRL Mice," *Int Arch. Allergy Appl. Immunol.* - 88:394-401 (1989)
- Ozols, R.F., "Paclitaxel Plus Carboplatin in the Treatment of Ovarian Cancer," *Seminars in Oncology* 26(1)(Supp.2 :84-89 (1999)
- Pestell, K.E., et al., "Characterisation of the P53 Status, BCL-2 Expression and Radiation and Platinum Drug Sensitivity of a Panel of Human Ovarian Cancer Cell Lines," *Int J. Cancer* - 77:913-918 1998
- Raynaud, F.I., et al., "Intracellular Metabolism of the Orally Active Platinum Drug JM216: Influence of Glutathione Levels," *Br. J. Cancer* -74(3) :380-386 1996
- Russell, J.H., et al., "Mature T Cells of Autoimmune *lpr/lpr* Mice have a Defect in Antigen-Stimulated Suicide," *Proc. Nat. Acad. Sci. USA* - 90:4409-4413 1993
- Sakata, K., et al., "Role of Fas/FasL Interaction in Physiology and Pathology: The Good and the Bad," *Clinical Immunology and Immunopathology* - 87(1):1-7 1998
- Sandstrom, P.A., et al., "Autocrine Production of Extracellular Catalase Prevents Apoptosis of the Human CEM T-Cell Line in Serum-Free Medium," *Proc. Natl. Acad. Sci. USA*-90:4708-4712 1993
- Schoemaker, H., et al., "Specific High-Affinity Binding Sites for [<sup>3</sup>H]Ro5-4864 in Rat Brain and Kidney," *The Journal of Pharmacology and Experimental Therapeutics* - 225(1)61-69 1983

- Schwab, M., et al., "Amplified DNA with Limited Homology to *myc* Cellular Oncogene is Shared by Human Neuroblastoma Cell Lines and a Neuroblastoma Tumour," *Nature* -305:245-248 1983
- Scott, C.F., et al., "Comparison of Antigen-Specific T Cell Responses in Autoimmune MRL/mp-Ipr/lpr and MRL/Mp-++ Mice," *The Journal of Immunology* - 1322 :633-639 1984
- Sentman, C.L., et al., "bcl-2 Inhibits Multiple Forms of Apoptosis but not Negative Selection in Thymocytes," *Cell* 67:879-886 1991
- Sheppard, R.C., et al., "Acid-Labile Resin Linkage Agents for Use in Solid Phase Peptide Synthesis;" *Int J. Peptide Protein Res.* - 20:451-454 1982
- Stevens, S.Y., et al., "Non Nucleic Acid Inhibitors of Protein-DNA Interactions Identified Through Combinatorial Chemistry," *J. Am. Chem. Soc.* -118:10650-10651 1996
- Sugimoto, T., et al., "Determination of Cell Surface Membrane Antigens Common to Both Human Neuroblastoma and Leukemia-Lymphoma Cell Lines by a Panel of 38 Monoclonal Antibodies," *JNCI-73(1):51-57* 1984
- Swanson, P.C., et al., "High Resolution Epitope Mapping of an Anti-DNA Autoantibody Using Model DNA Ligands," *J. Immunology* -152(5):2601-2612 1994
- Swanson, P.C., et al., "Ligand Recognition by Murine Anti-DNA Autoantibodies," *J. Clin. Invest* - 97(7):1748-1760 1996
- Takahashi, T., et al., "Generalized Lymphoproliferative Disease in Mice, Caused by a Point Mutation in the Fas Ligand;" *Cell* 76:969-976 1994
- Theofopoulos, AN, et al., "Murine Models of Systemic Lupus Erythematosus," *Advances in Immunology* - 37:269-390 1985
- Thompson, C.B., "Apoptosis in the Pathogenesis and Treatment of Disease," *Science* 267:1456-1462 1995
- Watanabe-Fukunaga, R., et al., "Lymphoproliferation Disorder in Mice Explained by Defects in Fas Antigen that Mediates Apoptosis," *Nature* - 356:314-317 1992


- White, E., "Life, Death, and the Pursuit of Apoptosis," *Genes & Development* - 10:1-15 1996
- Wu, G.Y., et al., "Receptor-Mediated in Vitro Gene Transformation by a Soluble DNA Carrier System," *The Journal of Biological Chemistry* 262(10):4429-4432 1987
- Wyllie, A.H., "The Genetic Regulation of Apoptosis," *Current Opinion in Genetics & Development* - 5:97-104 1995
- Zamzami, N., et al., "Mitochondrial Control of Nuclear Apoptosis," *J. Exp. Med.* - 183:1533-1544 1996
- Zoratti, M., et al., "The Mitochondrial Permeability Transition," *Biochimica et Biophysica Acta* - 1241:139-176 (1995)
- Blum, P., et al., "Stiff-Person Syndrome: An Autoimmune Disease," *Movement Disorders* - 6(1):12-20 (1991)
- Malgrange, B., et al., " $\beta$ -Carbolines Induce Apoptotic Death of Cerebellar Granule Neurones in Cultures," *NeuroReport* - 7(18):3041-3045 (1996)
- Miller, K.A., et al., "Benzodiazepines Prevent Neuronal Death by Apoptosis & Necrosis in the Gerbil Hippocampus Following Transient Cerebral Ischemia," *Society for Neuroscience Abstracts* - 24(1-2):979 (1998)
- Schlumpf, M., et al., "Delayed Developmental Immunotoxicity of Prenatal Benzodiazepines," *Toxic. In Vitro* - 3(5):1061-1065(1994).
- Tanimoto, Y., et al., "Benzodiazepine Receptor Agonists Modulate Thymocyte Apoptosis Through Reduction of the Mitochondrial Transmembrane Potential," *Jpn. J. Pharmacol.* - 79:177-183 (1999)
- Taupin, V., et al., "Endogenous Anxiogenic peptide, ODN-Diazepam-Binding Inhibitor, and Benzodiazepines Enhance the Production of Interleukin-1 and Tumor Necrosis Factor by Human Monocytes," *Lymphokine and Cytokine Research* - 10(1):7-13 (1991)
- Lowman *et al.*, *J. Biol.Chem.* 266:10982 [1991]
- Fuh *et al.*, *Science*, 256:1677 [1992]
- Colosi *et al.*, *J. Biol. Chem.*, 268:12617 [1993]
- A. Monks *et al.*, *J. Natl. Cancer Inst.*, 83:757-766 [1991]



- K.D. Paull *et al.*, J. Natl. Cancer Inst., 81:1088-1092 [1989] (Abstract only)
- E.D. Kerver *et al.*, Histochem. J., 29:229-237 [1997] (Abstract only)
- P.C. Swanson *et al.*, Biochemistry, 35:1624-1633 [1996] (Abstract only)

This Information Disclosure Statement under 37 C.F.R. §§ 1.56 and 1.97 is not to be construed as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one or more of these citations constitutes prior art.

Dated: June 16, 2004



Robert A. Goetz  
Registration No. 55,210  
MEDLEN & CARROLL, LLP  
101 Howard Street, Suite 305  
San Francisco, California 94105  
608/218-6900

FORM PTO-1449 (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use Several Sheets If Necessary) (37 CFR § 1.98(b))		U.S. Department of Commerce Patent and Trademark Office		Attorney Docket No.: UM-08192		Serial No.: 10/634,114		
				Applicant: Gary D. Glick <i>et al.</i>				
				Filing Date: 08/04/03		Group Art Unit:		
U.S. PATENT DOCUMENTS								
Examiner Initials	Cite No.	Serial / Patent Number	Issue Date	Applicant / Patentee	Class	Subclass	Filing Date	
	1	4,946,778	08/07/90	Ladner <i>et al.</i>	435	69.6	1/19/89	
	2	4,076,823	02/28/78	Wade <i>et al.</i>	424	269	08/18/77	
	3	4,110,337	08/29/78	Szarvasi	260	308	03/08/74	
	4	4,495,101	01/22/85	Klaubert <i>et al.</i>	260	239.3	04/28/83	
	5	4,751,223	06/14/88	Glamkowski <i>et al.</i>	514	219	10/14/86	
	6	5,776,946	06/07/98	McGeer <i>et al.</i>	514	307	08/28/95	
	7	5,324,726	06/28/94	Bock <i>et al.</i>	514	221	10/29/92	
	8	5,597,915	01/28/97	Chambers <i>et al.</i>	540	509	09/15/94	
	9	5,041,438	08/20/91	Hsu	514	221	10/30/89	
	10	5,861,380	01/19/99	Gyorkos <i>et al.</i>	514	19	12/06/96	
	11	6,004,942	12/21/99	Firestein <i>et al.</i>	514	44	12/21/99	
	12	6,080,588	06/27/00	Glick	436	508	06/27/00	
	13	3,415,814	12/10/68	Calabateas <i>et al.</i>	260	239.3	9/28/66	
	14	3,384,635	5/21/68	Calabateas <i>et al.</i>	160	239	6/18/65	
	15	3,261,828	7/19/66	Uskokovic <i>et al.</i>	160	239.4	10/14/62	
	16	5,288,514	2/22/94	Ellman	427	2	9/14/92	
	17	20010016583	08/23/01	Glick <i>et al.</i>	514	220	1/22/01	
FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS								
		Document Number	Publication Date	Country / Patent Office	Class	Subclass	Translation	
							Yes	No
	18	WO 00/19200	06/04/2000	PCT				
	19	0 349 949 A2	10/01/1990	EPO				
	20	WO 90/05305	17/5/90	PCT				
OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)								
	21	Köhler and Milstein, Nature, 256:495-497 [1975]						
	22	Kozbor <i>et al.</i> , Immunol. Today, 4:72 [1983]						
	23	Huse <i>et al.</i> , Science, 246:1275-1281 [1989]						
	24	Adachi, M., et al., "Aberrant Transcription Caused by the Insertion of an Early Transposable Element in an Intron of the Fas Antigen Gene of <i>lpr</i> Mice," PNAS. USA- 90:1756-1760 (1993)						
	25	Adelman, N.E., et al., "Treatment of (NZB X NZW)F1 Disease with Anti-I-A Monoclonal Antibodies; J. Exp. Med.- 158:1350-1355 (1983)						
	26	Baader, S.L., et al., "Uptake and Cytotoxicity of Ascorbic Acid and Dehydroascorbic Acid in Neuroblastoma (SK-N-SH) and Neuroendodermal (SK-N-LO) Cells," Anticancer Research-14:221-228 (1994)						
	27	Beale, P.J., et al., "BCL-2 Family Protein Expression and Platinum Drug Resistance in Ovarian Carcinoma," British Journal of Cancer- 82 (2) :436-440 (2000)						
	28	Cole <i>et al.</i> , in Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc., pp. 77-96 [1985]						
Examiner:					Date Considered:			
<b>EXAMINER:</b> Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								

FORM PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office		Attorney Docket No.: UM-08192	Serial No.: 10/634,114
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use Several Sheets If Necessary)				Applicant: Gary D. Glick <i>et al.</i>	
(37 CFR § 1.98(b))				Filing Date: 08/04/03	- Group Art Unit:
OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)					
29	Boojamra, C.G., et al., "Solid-Phase Synthesis of 1,4-Benzodiazepine-2,5-Diones. Library Preparation and Demonstration of Synthesis Generality," J. Org. Chem.-62:1240-1256 (1997)				
30	Bunin, B.A., et al., "A General and Expedient Method for the Solid-Phase Synthesis of 1,4-Benzodiazepine Derivatives," J. Am. Chem. Soc. -114:10997-10998 (1992)				
31	Bunin, B.A., et al., "The Combinatorial Synthesis and Chemical and Biological Evaluation of a 1,4-Benzodiazepine Library," PNAS USA-91:4708-4712 (1994)				
32	Chumakov, A.M., et al., "Analysis of p53 Transactivation Through High-Affinity Binding Sites," Oncogene-8:3005-3011 (1993)				
33	Cohen, P.L., et al., "Lpr and gld: Single Gene Models of Systemic Autoimmunity and Lymphoproliferative Disease," Annu. Rev. Immunol. - 9:243-269 (1991)				
34	Crabtree, R.H., "A New Type of Hydrogen Bond," Science 282:2000-2001 1998				
35	Desoize, B., "Anticancer Drug Resistance and Inhibition of Apoptosis," Anticancer Research -14:2291-2294 1994				
36	Doble, A., et al., "Labelling of Peripheral-Type Benzodiazepine Binding Sites in Human Brain with [ <sup>3</sup> H]11195: Anatomical and Subcellular Distribution," Brain Research Bulletin, 18:49-61 1987				
37	Donadio, J.V., et al., "Immunosuppressive Drug Therapy in Lupus Nephritis," American Journal of Kidney Diseases - 21(3):239-250 1993				
38	Ermak, T.H., et al., "Treatment of Murine Lupus with Monoclonal Antibody to L3T4," Laboratory Investigation - 61(4):447-456 1989				
39	Gallant, J.E., et al., "Incidence and Natural History of Cytomegalovirus Disease in Patients with Advanced Human Immunodeficiency Virus Disease Treated with Zidovudine," The Journal of Infectious Diseases -166:1223-1227 1992				
40	Garcia-Calvo, M., et al., "Inhibition of Human Caspases by Peptide-Based and Macromolecular Inhibitors," The Journal of Biological Chemistry - 273(49):32608-32613 1998				
41	Gorczyca, W., et al., "Induction of DNA Strand Breaks Associated with Apoptosis During Treatment of Leukemias," Leukemia - 7(5):659-670 1993				
42	Gordon, C., et al., "Chronic Therapy with Recombinant Tumor Necrosis Factor- $\alpha$ in Autoimmune NZB/NZW F1 Mice," Clinical Immunology and Immunopathology- 52:421-434 1989				
43	Hahn, B.H., et al., "Influence of Cyclophosphamide and Other Immunosuppressive Drugs on Immune Disorders and Neoplasia in NZB/NZW Mice," Arthritis and Rheumatism -18(2):145-152 1975				
44	Hang, L., et al., "A Spontaneous Rheumatoid Arthritis-Like Disease in MR1 Mice," J. Exp. Med. -155:1690-1701 1982				
45	Horowitz, R.E., et al., "Cyclophosphamide Treatment of Mouse Systemic Lupus Erythematosus," Laboratory Investigation - 21(3):199-206 1969				
46	Itoh, N., et al., "The Polypeptide Encoded by the cDNA for Human Cell Surface Antigen Fas Can Mediate Apoptosis," Cell - 66:233-243 1991				
47	Koopman, W.J., et al., "The MRL-lpr/lpr Mouse. A Model for the Study of Rheumatoid Arthritis," Scand. J. Rheumatology - Suppl 75:284-289 1988				
48	Korsmeyer, S.J., "Bcl-2 Initiates a New Category of Oncogenes: Regulators of Cell Death," Blood - 80(4):879-886 1992				
49	Liu, J.R., et al., "Bcl-2 is Expressed in Ovarian Carcinoma and Modulates Chemotherapy-induced Apoptosis," Gynecologic Oncology - 70:398-403 1998				
50	Los, M., et al., "The Role of Caspases in Development, Immunity, and Apoptotic Signal Transduction: Lessons from Knockout Mice," Immunity -10:629-639 1999				
51	Luria, et al., "General Virology - 3rd edition, . 436-446 1978 - Eds. John Wiley & Sons, New York				
52	Gordon, E.M., et al., "Applications of Combinatorial Technologies to Drug Discovery. 2. Combinatorial Organic Synthesis, Library Screening Strategies, and Future Directions," Journal of Medicinal Chemistry- 37(10):1385-1401 1994				
Examiner:				Date Considered:	
<b>EXAMINE:</b> Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

FORM PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office		Attorney Docket No.: UM-08192	Serial No.: 10/634,114
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use Several Sheets If Necessary)				Applicant: Gary D. Glick <i>et al.</i>	
* (37 CFR § 1.98(b))				Filing Date: 08/04/03	Group Art Unit:
OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)					
	53	Marino, M., et al., "Prevention of Systemic Lupus Erythematosus in MRL/lpr Mice by Administration of an Immunoglobulin-Binding peptide," Nature Biotechnology -18:735-739 2000			
	54	McDonnell, T.J., et al., "Progression from Lymphoid Hyperplasia to High-Grade Malignant Lymphoma in Mice Transgenic for the t(14;18)," Nature - 349:254-256 1991			
	55	Nagata, S., "Human Autoimmune Lymphoproliferative Syndrome, a Defect in the Apoptosis-Inducing Fas Receptor: A Lesson from the Mouse Model," J. Hum. Genet - 43:2-8 1998			
	56	Okuyama, H., et al., "Analysis of Defective Delayed-Type Hypersensitivity in Autoimmune Mice Bearing <i>lpr</i> Gene," Clin. Ex p. Immunol - 63:87-94 1986			
	57	Okuyama, H., et al., "Effect of Cyclophosphamide Pretreatment on Defective Delayed-Type Hypersensitivity in Autoimmune-Prone MRL Mice," Int Arch. Allergy Appl. Immunol. - 88:394-401 (1989)			
	58	Ozols, R.F., "Paclitaxel Plus Carboplatin in the Treatment of Ovarian Cancer," Seminars in Oncology 26(1)(Supp.2):84-89 (1999)			
	59	Pestell, K.E., et al., "Characterisation of the P53 Status, BCL-2 Expression and Radiation and Platinum Drug Sensitivity of a Panel of Human Ovarian Cancer Cell Lines," Int J. Cancer - 77:913-918 1998			
	60	Raynaud, F.I., et al., "Intracellular Metabolism of the Orally Active Platinum Drug JM216: Influence of Glutathione Levels," Br. J. Cancer - 74(3):380-386 1996			
	61	Russell, J.H., et al., "Mature T Cells of Autoimmune <i>lpr/lpr</i> Mice have a Defect in Antigen-Stimulated Suicide," Proc. Nat. Acad. Sci. USA - 90:4409-4413 1993			
	62	Sakata, K., et al., "Role of Fas/FasL Interaction in Physiology and Pathology: The Good and the Bad," Clinical Immunology and Immunopathology - 87(1):1-7 1998			
	63	Sandstrom, P.A., et al., "Autocrine Production of Extracellular Catalase Prevents Apoptosis of the Human CEM T-Cell Line in Serum-Free Medium," Proc. Natl. Acad. Sci. USA-90:4708-4712 1993			
	64	Schoemaker, H., et al., "Specific High-Affinity Binding Sites for [ <sup>3</sup> H]Ro5-4864 in Rat Brain and Kidney," The Journal of Pharmacology and Experimental Therapeutics - 225(1):61-69 1983			
	65	Schwab, M., et al., "Amplified DNA with Limited Homology to <i>myc</i> Cellular Oncogene is Shared by Human Neuroblastoma Cell Lines and a Neuroblastoma Tumour," Nature -305:245-248 1983			
	66	Scott, C.F., et al., "Comparison of Antigen-Specific T Cell Responses in Autoimmune MRL/mp- <i>lpr/lpr</i> and MRL/Mp- <i>+</i> Mice," The Journal of Immunology - 132:633-639 1984			
	67	Sentman, C.L., et al., "bcl-2 Inhibits Multiple Forms of Apoptosis but not Negative Selection in Thymocytes," Cell 67:879-886 1991			
	68	Sheppard, R.C., et al., "Acid-Labile Resin Linkage Agents for Use in Solid Phase Peptide Synthesis," Int J. Peptide Protein Res. - 20:451-454 1982			
	69	Stevens, S.Y., et al., "Non Nucleic Acid Inhibitors of Protein-DNA Interactions Identified Through Combinatorial Chemistry," J. Am. Chem. Soc. -118:10650-10651 1996			
	70	Sugimoto, T., et al., "Determination of Cell Surface Membrane Antigens Common to Both Human Neuroblastoma and Leukemia-Lymphoma Cell Lines by a Panel of 38 Monoclonal Antibodies," JNCI-73(1):51-57 1984			
	71	Swanson, P.C., et al., "High Resolution Epitope Mapping of an Anti-DNA Autoantibody Using Model DNA Ligands," J. Immunology - 152(5):2601-2612 1994			
	72	Swanson, P.C., et al., "Ligand Recognition by Murine Anti-DNA Autoantibodies," J. Clin. Invest - 97(7):1748-1760 1996			
	73	Takahashi, T., et al., "Generalized Lymphoproliferative Disease in Mice, Caused by a Point Mutation in the Fas Ligand," Cell 76:969-976 1994			
	74	Theofopoulos, AN, et al., "Murine Models of Systemic Lupus Erythematosus," Advances in Immunology - 37:269-390 1985			
	75	Thompson, C.B., "Apoptosis in the Pathogenesis and Treatment of Disease," Science 267:1456-1462 1995			
	76	Watanabe-Fukunaga, R., et al., "Lymphoproliferation Disorder in Mice Explained by Defects in Fas Antigen that Mediates Apoptosis," Nature - 356:314-317 1992			
	77	White, E., "Life, Death, and the Pursuit of Apoptosis," Genes & Development - 10:1-15 1996			
Examiner:			Date Considered:		
<b>EXAMINER:</b> Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

FORM PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office		Attorney Docket No.: UM-08192	Serial No.: 10/634,114
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use Several Sheets If Necessary)				Applicant: Gary D. Glick <i>et al.</i>	
				Filing Date: 08/04/03	Group Art Unit:
(37 CFR § 1.98(b))					
OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)					
	78	Wu, G.Y., et al., "Receptor-Mediated in Vitro Gene Transformation by a Soluble DNA Carrier System," The Journal of Biological Chemistry 262(10):4429-4432 1987			
	79	Wyllie, A.H., "The Genetic Regulation of Apoptosis," Current Opinion in Genetics & Development - 5:97-104 (1995)			
	80	Zamzami, N., et al., "Mitochondrial Control of Nuclear Apoptosis," J. Ex p. Med. - 183:1533-1544 1996			
	81	Zoratti, M., et al., "The Mitochondrial Permeability Transition," Biochimica et Biophysica Acta - 1241:139-176 (1995)			
	82	Blum, P., et al., "Stiff-Person Syndrome: An Autoimmune Disease," Movement Disorders - 6(1):12-20 (1991)			
	83	Malgrange, B., et al., "β-Carbolines Induce Apoptotic Death of Cerebellar Granule Neurones in Cultures," NeuroReport - 7(18):3041-3045 (1996)			
	84	Miller, K.A., et al., "Benzodiazepines Prevent Neuronal Death by Apoptosis & Necrosis in the Gerbil Hippocampus Following Transient Cerebral Ischemia," Society for Neuroscience Abstracts - 24(1-2):979 (1998)			
	85	Schlumpf, M., et al., "Delayed Developmental Immunotoxicity of Prenatal Benzodiazepines," Toxic. In Vitro - 3(5):1061-1065(1994).			
	86	Tanimoto, Y., et al., "Benzodiazepine Receptor Agonists Modulate Thymocyte Apoptosis Through Reduction of the Mitochondrial Transmembrane Potential," Jpn. J. Pharmacol. - 79:177-183 (1999)			
	87	Taupin, V., et al., "Endogenous Anxiogenic peptide, ODN-Diazepam-Binding Inhibitor, and Benzodiazepines Enhance the Production of Intedeukin-1 and Tumor Necrosis Factor by Human Monocytes," Lymphokine and Cytokine Research - 10(1):7-13 (1991)			
	88	Lowman <i>et al.</i> , J. Biol.Chem. 266:10982 [1991]			
	89	Fuh <i>et al.</i> , Science, 256:1677 [1992]			
	90	Colosi <i>et al.</i> , J. Biol. Chem., 268:12617 [1993]			
	91	A. Monks <i>et al.</i> , J. Natl. Cancer Inst., 83:757-766 [1991]			
	92	K.D. Paull <i>et al.</i> , J. Natl. Cancer Inst., 81:1088-1092 [1989] (Abstract only)			
	93	E.D. Kerver <i>et al.</i> , Histochem. J., 29:229-237 [1997] (Abstract only)			
	94	P.C. Swanson <i>et al.</i> , Biochemistry, 35:1624-1633 [1996] (Abstract only)			
Examiner:				Date Considered:	
<b>EXAMINE9:</b> Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					